Article
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.
Journal of clinical pharmacology - 1 Jun 2011
Ward Robert M, Kearns Gregory L, Tammara Brinda, Bishop Phyllis, O'Gorman Molly A, James Laura P, Katz Mitchell H, Maguire Mary K, Rath Natalie, Meng Xu, Comer Gail M
Abstract excerpt
Children with gastroesophageal reflux disease (GERD) may benefit from gastric acid suppression with proton pump inhibitors such as pantoprazole. Effective treatment with pantoprazole requires correct dosing and understanding of the drug's kinetic profile in children. The aim of these studies was to characterize the pharmacokinetic (PK) profile of single and multiple doses of pantoprazole delayed-release tablets...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.